STAY INFORMED. VISIT NHIA.ORG/COVID19 FOR INFORMATION AND RESOURCES ABOUT CORONAVIRUS DISEASE (COVID-19).
New publicly available data from the Centers for Medicare and Medicaid Services for CY 2019 shows that beneficiary utilization of the Part B DMEPOS home
NHIF Research Rate of Discontinuation from Home Infusion Therapy Due to Adverse Drug Reactions and Unplanned Hospitalizations – A Pilot Study September/October 2021 By Danell
Regulatory update NHIA Submits Comments on Proposed 2022 Physician Fee Schedule September 13, 2021 On September 10, NHIA submitted comments to the Centers for Medicare
This new scholarly journal will feature independent research and studies related to infused therapies, patient outcomes, medication safety, economic analyses, and case studies.
On September 8, a group of stakeholders, including home infusion providers, patient advocacy groups, professional societies, and industry suppliers, sent a letter to leaders in the House of Representatives and the Senate encouraging them to pass the Preserving Patient Access to Home Infusion Act (S 2652; H.R. 5067).
Regulatory update NHIA Comments on Medicare home health proposed rule August 27, 2021 NHIA has submitted comments to CMS on the CY 2022 Home Health
PRESS RELEASE NHIA APPLAUDS HOUSE INTRODUCTION OF BIPARTISAN HOME INFUSION LEGISLATION FOR IMMEDIATE RELEASEContact: Shea McCarthyDirector of Legislative Affairsshea.mccarthy@nhia.org202-285-3866 Alexandria, Va. (August 23, 2021) — Today,
PRESS RELEASE BIPARTISAN LEGISLATION WOULD MAINTAIN HOME INFUSION ACCESS AMONG MEDICARE BENEFICIARIES FOR IMMEDIATE RELEASEContact: Shea McCarthyDirector of Legislative Affairsshea.mccarthy@nhia.org202-285-3866 Alexandria, Va. (August 5, 2021)
Alexandria, VA. (June 16, 2021)—On June 15, a U.S. district court dismissed NHIA’s case over the implementation of a Medicare home infusion therapy services benefit
New publicly available data from the Centers for Medicare and Medicaid Services for CY 2019 shows that beneficiary utilization of the Part B DMEPOS home
NHIF Research Rate of Discontinuation from Home Infusion Therapy Due to Adverse Drug Reactions and Unplanned Hospitalizations – A Pilot Study September/October 2021 By Danell
Regulatory update NHIA Submits Comments on Proposed 2022 Physician Fee Schedule September 13, 2021 On September 10, NHIA submitted comments to the Centers for Medicare
This new scholarly journal will feature independent research and studies related to infused therapies, patient outcomes, medication safety, economic analyses, and case studies.
On September 8, a group of stakeholders, including home infusion providers, patient advocacy groups, professional societies, and industry suppliers, sent a letter to leaders in the House of Representatives and the Senate encouraging them to pass the Preserving Patient Access to Home Infusion Act (S 2652; H.R. 5067).
Regulatory update NHIA Comments on Medicare home health proposed rule August 27, 2021 NHIA has submitted comments to CMS on the CY 2022 Home Health
PRESS RELEASE NHIA APPLAUDS HOUSE INTRODUCTION OF BIPARTISAN HOME INFUSION LEGISLATION FOR IMMEDIATE RELEASEContact: Shea McCarthyDirector of Legislative Affairsshea.mccarthy@nhia.org202-285-3866 Alexandria, Va. (August 23, 2021) — Today,
PRESS RELEASE BIPARTISAN LEGISLATION WOULD MAINTAIN HOME INFUSION ACCESS AMONG MEDICARE BENEFICIARIES FOR IMMEDIATE RELEASEContact: Shea McCarthyDirector of Legislative Affairsshea.mccarthy@nhia.org202-285-3866 Alexandria, Va. (August 5, 2021)
Alexandria, VA. (June 16, 2021)—On June 15, a U.S. district court dismissed NHIA’s case over the implementation of a Medicare home infusion therapy services benefit
